Securities Fraud Investigation Into Profound Medical Corp. (PROF) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROFOUND MEDICAL CORP. (PROF), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On March 7, 2025, Profound disclosed that it had “identified an error which overstated revenue by $472,000 in the first quarter of 2024.” The Company stated correction of this error “reduced revenue previously presented . . . in the first quarter, and in the year-to-date figures in the second and third quarters of 2024.” The Company advised that the affected financial statements “should no longer be relied upon as a result of the foregoing error.”

On this news, Profound’s stock price fell $0.43, or 5.9%, to close at $6.86 per share on March 7, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Profound securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,

2121 Avenue of the Stars, Suite 800,

Century City, California 90067

Call us at: 310-914-5007

Email us at: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com.

Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.